Lake Street lowered the firm’s price target on Evaxion Biotech (EVAX) to $9 from $11 and keeps a Buy rating on the shares. The firm updated the outlook for potential licensing deals after Evaxion reported Q4 results and provided a corporate update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVAX:
- Evaxion Posts Transformational 2025, Extends Cash Runway Into 2027 on MSD Deal and Vaccine Progress
- Evaxion Biotech reports Q4 EPS (2c) vs. (21c) last year
- Evaxion Biotech sees FY26 capex ‘similar’ to FY25
- Evaxion Biotech sees cash runway into 2H27
- Evaxion Delays 2025 Annual Report Filing Due to Technical Issues